Benchling Acquires PipeBio to Enhance AI-Powered Antibody Discovery

by Roman Kasianov       News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

  
Topics: Tools & Methods   
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email   |  

Benchling, a cloud-based R&D software provider, has acquired PipeBio, a bioinformatics company specializing in high-throughput sequence analysis for biologics discovery. This collaboration brings together Benchling’s digital R&D tools with PipeBio’s sequence analysis platform to create a solution for antibody discovery and development.

Why PipeBio? As the demand for tools in antibody research grows, PipeBio’s platform is designed to handle large-scale sequence analysis, offering researchers capabilities to screen millions of sequences, visualize data, and identify candidates for development. Founded in 2020, PipeBio’s cloud-native product is used for biologics discovery, particularly in the early stages. Joining Benchling enables PipeBio to integrate additional resources and further develop its offerings within the biologics research space.

Complementary Strengths

  • Benchling: Benchling offers R&D management tools such as electronic lab notebooks (ELNs) and lab information management systems (LIMS), aimed at helping scientists manage experiments, track data, and streamline workflows. The platform facilitates collaboration between experimental and computational research teams, connecting wet lab data with computational models.
  • PipeBio: PipeBio’s platform supports sequence analysis and screening, allowing researchers to process large numbers of sequences and identify key candidates. Additionally, the platform integrates AI-driven models to assist in guiding antibody candidate selection and decision-making within biologics R&D.

With this acquisition, Benchling and PipeBio plan to enhance biologics research through an integrated platform that spans the entire discovery process:

  • Sequence Intelligence: PipeBio’s capabilities in sequence analysis are intended to aid in the design and registration of complex large molecules, in line with trends in biologics R&D.
  • Screening and Hit Selection: The integration will provide tools to connect sequence, structure, and function data, supporting researchers in selecting candidates for further development.
  • AI-Enabled Discovery: The inclusion of AI models and integration capabilities aims to streamline the collaboration between experimental and computational teams, allowing predictions to inform the discovery and engineering process.
Image credit: Liudmyla Lishchyshyna

Topics: Tools & Methods   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email